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Receptor activator of NFkB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both
in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared
RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by
immunohistochemistry in 74 bonemetastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40
cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive
and, among these, 40 (59.5%) showed more than 50% of positive tumor cells. The median percentage of RANK-positive cells was 60% in
primary tumors andmetastases, without any statistically signiﬁcant difference between the two groups (P¼ 0.194). The same percentage
was obtained by considering only cases with availability of samples both from primary and metastasis. Our study shows that RANK is
expressed by solid tumors, with high concordance between bone metastasis and corresponding primary tumor. These data highlight the
central role of RANK/RANKL/OPG pathway as potential therapeutic target not only in bone metastasis management, but also in the
adjuvant setting. J. Cell. Physiol.
J. Cell. Physiol. 226: 780–784, 2011.  2010 Wiley-Liss, Inc.
Receptor activator of NFkB ligand (RANKL)/RANK/
osteoprotegerin (OPG) pathway represents a key regulator of
bone metabolism both in normal and pathological conditions,
including bonemetastases. RANK is expressed at the surface of
osteoclasts and it is an essential signaling receptor in osteoclast
differentiation. RANKL is preferentially expressed on
committed pre-osteoblastic cells and, upon binding to RANK,
has been shown to both activate mature osteoclasts and
mediate osteoclastogenesis in presence of macrophage-colony
stimulating factor (M-CSF). OPG, produced by osteoblast
lineage cells, acts as a decoy receptor and inhibits osteoclast
formation, function, and survival by preventing RANKL binding
to RANK (Boyce and Xing, 2008). RANK expression has been
found in osteosarcoma cell lines from human origin together
with some human osteosarcoma specimens, both at
transcriptional and protein level (Wittrant et al., 2006; Mori
et al., 2007a).
However, RANK expression is not restricted to bone cells
and has been also observed in other tissues including epithelial
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cells ofmammary gland, lung, brain, and kidney (Nakagawa et al.,
1998; Hsu et al., 1999; Srivastava et al., 2003). Moreover,
RANK is also expressed in several cancer cell lines where
seems to play a central role in tumor cell migration and invasion
(Mori et al., 2007b). As recently demonstrated, this pathway
has been found to be disregulated in several solid tumors, such
as breast cancer, malignant bone tumors, multiple myeloma,
giant cell tumors of bone, chondroblastoma, neuroblastoma,
squamous cell carcinoma, and Hodgkin disease (Mori et al.,
2007b).
Additionally, Jones et al. (2006) have reported the
expression of functional RANK in human breast and prostate
cancer and mouse melanoma cell lines. Moreover, Chen et al.
studied RANKL, RANK, and OPG expression in primary
and metastatic prostate cancer samples. They found that the
expression of these molecules was signiﬁcantly higher in
metastatic prostate cancer than in primary carcinoma (Chen
et al., 2006). Similarly, Brown et al. (2004) analyzed primary and
metastatic prostate cancer samples and showed that the
proportion of tumor cells expressing RANKL was signiﬁcantly
increased in bone metastases compared with metastases in
other sites or with the primary tumor. Furthermore, Mori et al.
evaluated cases of primary HCC and observed that RANKL
expression in HCC cells is correlated with the development of
bone metastases after hepatic resection (Sasaki et al., 2007).
Moreover, it has been demonstrated that RANKL triggers
cytoskeletal changes and migration of several human epithelial
tumor cells (including primary breast cancer cells) expressing
RANK (Jones et al., 2006).
Taken together, these ﬁndings suggest that, upon RANKL
activation, RANK may stimulate primary tumor cells to
migrate into the bone and may induce the bone metastases
process, with additional autocrine and paracrine mechanisms.
To our knowledge, there are no previous studies
investigating RANK expression in primary tumors and
corresponding bone metastases. Thus, we studied RANK
expression by immunohistochemistry (IHC) in a large
heterogeneous cohort of human primary solid tumors and
related bone metastases, in order to compare RANK
expression between the two sites of tumoral disease.
These results drive us to investigate if RANK expression
depends more on bone microenvironment or on primary
tumor histology and whether these molecules could
represent ubiquitariously expressed targets for anticancer
therapies.
Materials and Methods
Patients
Surgical biopsy samples from 74 patients with bone metastases
were examined in this study. The period of accrual was March
2006–January 2009. All patients had histological diagnosis of solid
tumor (regardless of treatment performed) and signed the
informed consent. For 40 patients, the parafﬁned samples of both
primary and metastatic tumors were available. For 34 patients we
only examined the samples from bone metastasis. Exclusion
criteria were any previous hematological disease (myelodisplastic,
lymphoproliferative, and myeloproliferative syndromes) and
assumption of drugs with high osteotrophism, such as
bisphosphonates, calcitonin, and Vitamin D. Table 1 shows the
distribution of patients included in the study, by site of primary
tumor.
Immunohistochemistry
IHC experiments were performed on surgical pathology
specimens used for diagnosis. Samples were ﬁxed in 4% neutral
buffered formaldehyde and, in case of bone biopsies, were
demineralized by EDTA solution (1,000ml water, 37,22 g
ethylenediaminetetraacetic acid disodium salt dehydrate, 70ml
HCL 37%) for less than 3 h. Bones specimenswerewashed inwater
before parafﬁn embedding.
Representative tumor blocks were sectioned at 3mm thickness.
IHC was performed by the streptavidin–biotin method.
Endogenous peroxidase in the section was blocked by incubation
with 3% hydrogen peroxide. Amousemonoclonal antibody against
RANK protein (clone 80707, R&D Systems, Inc., Minneapolis, MN)
was used as primary antibody at a concentration of 25mg/ml.
Sections were incubated with LSAB2 (Dakocytomation,
Carpinteria, CA). 3-30-Diaminobenzidine (DAB)was used for color
development and hematoxylin was used for counterstaining.
Negative controls were obtained by omitting primary antibodies.
Scoring for RANKwas based on the relative staining intensity of
tumor cells compared to the RANK staining of osteoclasts (bone
metastatic lesions) and tissue associated macrophages (primary
tumors). These internal references were then used as internal
positive controls between slides and samples as well as for the
staining procedure. Each pathologic tissue was evaluated by
comparison with the internal controls. Staining intensity was
graded as absent (0), positive but less intense than internal control
tissue (1þ), positive like internal control tissue (2þ), positive but
more intense than internal control tissue (3þ). Samples with
TABLE 1. Number of samples for each type of primary tumor and metastases
Primary Metastatic
No. of
lesions
No. (%) of lesions
RANK positive in >50%
of tumor tissue
No. of
lesions
No. (%) of lesions
RANK positive in >50%
of tumor tissue
Breast 14 8 (57.1%) 19 13 (68.4%)
Colorectal 6 4 (66.6%) 8 5 (62.5%)
Renal 5 2 (40%) 6 2 (33.3%)
Lung 1 1 (100%) 8 7 (87.5%)
Prostate 4 2 (50%) 7 2 (28.5%)
Thymic 1 0 (0%) 1 0 (0%)
Esophageal 1 1 (100%) 1 1 (100%)
Bladder 1 0 (0%) 2 1 (50%)
Thyroid 2 0 (0%) 5 0 (0%)
Hepatic 1 1 (100%) 2 1 (50%)
Cervical 2 2 (100%) 2 2 (100%)
Endometrial 2 1 (50%) 2 2 (100%)
Biliary tract 1 0 (0%)
Salivary glands 2 1 (50%)
Squamous 1 1 (100%)
Malignant melanoma 1 1 (100%)
Unknown 6 1 (16.6%)
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regions of heterogeneous staining intensities of RANK were
scored and the percentage of each area was recorded. Tumor cells
with an immunostaining intensity of 2þ and 3þwere considered as
positive. Immunostaining was assessed by two independent
pathologists blinded to clinical characteristics and outcomes.
Statistical analysis
Wilcoxon signed-rank test was used to assess differences in RANK
expression between primary and related metastatic lesions.
P¼ 0.05 was considered as statistically signiﬁcant. SPSS software
(version 14.00; SPSS, Inc., Chicago, IL) was used for statistical
analysis.
Results
RANK protein expression
RANK immunostaining, if present, was observed both at the
plasma membrane and the cytoplasm of tumor cells (Fig. 1).
Consistently with ﬁndings from other groups, RANK staining
was also constantly found in osteoclast cells of bone tissue
around metastatic lesions (Nakagawa et al., 1998) and in tissue
associate macrophages within and around primary cancers (van
Ravenswaay Claasen et al., 1992; Lau et al., 2007). Thus, both
cell types were used as internal positive controls.
RANK expression in bone metastases
Sixty-six (89%) of the 74 bonemetastasis samples were RANK-
positive and, among these, 40 (59.5%) showed more than 50%
of positive tumor cells.
Themedian percentage of RANK-positive cells seemed to be
dependent on the tumor histotype, being 70% for breast, 60%
for colorectal, 30% for renal, 100% for lung, and 40% for
prostate cancer. We did not perform analysis of differences
because of the heterogeneous distribution of the cases.
To note, the only case of bonemetastasis from thymomawas
RANK-negative, whereas the median percentage of RANK-
positive cells was between 30% for tumor of unknown origin
and 100% for metastases from esophageal cancer. Speciﬁcally,
the median RANK expression was 40% in bladder cancer,
thyroid cancer and cholangiocarcinoma, 55% in salivary glands
tumors, 60% in hepatocarcinoma, 70% in cervical cancer, 75% in
endometrial cancer, 80% in squamous cancer, and 90% in
melanoma (Fig. 2).
RANK expression in primary tumors
Considering only the 40 primary tumors samples, 27 (67.5%)
were RANK-positive and 22 (55%) showed more than 50% of
positive tumor cells.
Also at primary sites, the median percentage of RANK-
positive cells seemed to be dependent on the tumor histotype,
being 65% for breast, 75% for colorectal, 25% for renal, 90% for
lung, and 55% for prostate cancer. The number of primary
lesions did not allow a reliable difference analysis evaluation.
Considering all the histotypes, we observed that RANK
expression was considerably variable among tumors. For
example, thymoma and bladder cancers were completely
negative, whereas the median percentage of RANK-positive
cells was between 15% and 85% in the other tumors (thyroid
cancer and cervical cancer, respectively). Speciﬁcally, RANK
expression was 30% in endometrial cancer, 60% in
hepatocarcinoma and 80% in esophageal cancer (Fig. 3).
Comparison of RANK expression between primary
tumors and bone metastases
To compare the expression of RANK in primary tumor and
metastasis, we calculated the median percentage of RANK-
positive cells in all the samples from the primaries versus
metastases. The median value of RANK-positive cells was 60%
in both groups. In terms of percentage of RANK-positive cells,
we did not ﬁnd any statistically signiﬁcant difference between
primary and metastases group (P¼ 0.194) (Fig. 4). Moreover,
we repeated the analysis including only patients with availability
of matched primary and metastasis tissue samples and we
Fig. 1. Immunohistochemical results. Image A shows a prostatic
bone metastasis in which the majority of tumor cells are positive for
RANK immunostaining. The black star is placed on the peripheral
bone tissue. In image B, one of the breast cancer studied. The tumor
cells are strongly positive for RANK immunostaining (red arrows).
The normal glandular epithelium is negative orweakly positive (black
arrows) conﬁrming the RANK protein overexpression of the tumor
tissue. Image C shows osteoclast cells positive for RANK staining
(black arrows). This picture is taken from a perimetastatic area.
OriginalmagniﬁcationA,C400T, B100T. [Colorﬁgure canbeviewed
in the online issue, which is available at wileyonlinelibrary.com.]
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observed a median percentage of RANK-positive cells of 60%
for the ‘‘primary’’ and 55% for the ‘‘metastasis’’ group
(P¼ 0.528) (Fig. 5). Moreover, considering only patients with
breast cancer (14 primaries and 19 bone metastases), we did
not observe any statistically signiﬁcant difference (P¼ 0.854)
between number of RANK-positive cells in primary (65%)
versus bone metastasis (70%). No statistical differences were
found between primary and metastatic prostate and renal
cancers (P¼ 0.775 and 0.925, respectively).
Conclusions
RANK/RANKL/OPG pathway represents a new therapeutic
target in the treatment of osteoporosis and in the risk reduction
of skeletal related events in bone metastatic cancer patients
(Cummings et al., 2009; Fizazi et al., 2009; Smith et al., 2009).
Our study shows that RANK is expressed in a wide percentage
of bone metastases deriving from several different primary
histotypes and in a large part of corresponding primary solid
Fig. 2. shows the distribution of RANK-positive cells among the bone metastases.
Fig. 3. Distribution of RANK-positive cells among the primitive tumors.
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tumors. Further studies are obviously necessary to conﬁrm
these data and to verify the functional importance of RANK
expression in each histotype. However, these results open a
new scenario in which RANK/RANKL/OPG pathway could
become an optimal therapeutic target for anticancer therapy.
Moreover, we observed that RANK expression in primary
tumors and in the related bone metastases differs according to
the histotype and not according to the metastatization process
or to the bone biological microenvironment. There are tumors
expressing high levels of RANK both in primary and bone
metastasis (e.g., breast and colorectal cancers) compared to
others expressing low levels in both sites (e.g., prostate cancer).
Unfortunately, the heterogeneous distribution of primaries did
not allow a statistical analysis to compare the different levels of
RANKexpression according to thehistological originof tumors.
However, this study clearly shows for the ﬁrst time in
literature that, considering all primary sites, RANK expression
level in bonemetastases is, on average, not signiﬁcantly different
from the level detected in the related primary tumors. For this
reason, the amount of RANK expression in bone metastases
seems to be histotype-dependent. In fact, we found the same
concordance in RANK expression when we compared only
primary and related bone metastasis pairs, excluding the bone
metastases whose the corresponding primary tumors samples
were not available.
There are no previous studies comparing RANK expression
in bone metastatic tissue versus primary tumor tissue from the
same patient. If we consider previous series (comparing bone
metastasis with primary tumor from different patients), as for
prostate cancer, our results differ from those obtained byChen
et al. (2006). In particular, their study showed a greater RANK
expression in bone metastases compared with primary cancer,
while our work demonstrated a very similar level of expression
in primary cancer and in bone metastatic lesions. On the
contrary, regarding breast cancer, our data are consistent with
the observations from Bhatia et al. (2005), showing an almost
complete concordance of RANK expression between primary
tumors and related bone metastases.
In conclusion, on the basis of our data, RANK is expressed in
a large range of primary tumors and related bone metastases.
Whether this expression could represent a valid therapeutic
target, not only in bone metastasis management, but also as
treatment in advanced and adjuvant setting, is still an
unanswered question that needs to be investigated by
prospective randomized clinical trials.
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Fig. 4. Comparisonof theRANKexpressionbetween ‘‘primary’’ and
‘‘metastasis’’ considering all the samples. [Color ﬁgure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
Fig. 5. Comparisonof theRANKexpressionbetween ‘‘primary’’ and
‘‘metastasis’’consideringonlythesampleswithboththe‘‘primary’and
the ‘‘metastasis’’ available. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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